1. Ascic, Ervin, Åkerström, Fritiof, Sreekumar Nair, Malavika, Rosa, Fábio F, Pereira, Carlos-Filipe. 2024. In vivo dendritic cell reprogramming for cancer immunotherapy. In Science (New York, N.Y.), 386, eadn9083. doi:10.1126/science.adn9083. https://pubmed.ncbi.nlm.nih.gov/39236156/
2. Ziblat, Andrea, Horton, Brendan L, Higgs, Emily F, Sweis, Randy F, Gajewski, Thomas F. 2024. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. In Cell reports, 43, 114141. doi:10.1016/j.celrep.2024.114141. https://pubmed.ncbi.nlm.nih.gov/38656869/
3. McCutcheon, Sean R, Swartz, Adam M, Brown, Michael C, Antonia, Scott J, Gersbach, Charles A. 2023. Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens. In Nature genetics, 55, 2211-2223. doi:10.1038/s41588-023-01554-0. https://pubmed.ncbi.nlm.nih.gov/37945901/